Skip to main content

Peer Review reports

From: The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial

Original Submission
18 Dec 2017 Submitted Original manuscript
31 Dec 2017 Reviewed Reviewer Report - James Wason
16 Jan 2018 Author responded Author comments - Alina Striha
Resubmission - Version 2
16 Jan 2018 Submitted Manuscript version 2
18 Jan 2018 Editorially accepted
7 Mar 2018 Article published 10.1186/s13063-018-2524-8

You can find further information about peer review here.

Back to article page